Work

The effect of L-dopa and neuroprotective agents oncell replacement therapy for Parkinson’s disease.

Year: 2017
Type: dissertation
Abstract: Parkinson disease PD is the second most common neurodegenerative disease affecting 1.8% \nof population aged over 65 years. The current medications that control the symptoms of the \ndisease are associated with limited efficacy and induction of side effects (dyskinesia) at later \nstages of the disease. One promising future therapy in PD is cell replacement therapy, \nhowever clinical trials declared inconsistent outcomes and developing dyskinesia related to \nthe graft. Studies later suggested suboptimal conditions contributed on these outcomes. This \nthesis builds on this knowledge endeavouring to support cell transplantian therapy in \nParkinson disease in models that are more closely aligned to the clinic thorough considering \nanti-parkinsonian medications in the model. It is addressed the low survival and efficacy \nproblem of the transplanted cells examining neuroprotective agents that have previously \nshown the ability to protect nigrostriatal dopaminergic neurons against toxic challenges. In \naddition, this thesis characterises stem cell transplantation, the potential cell source for \ntransplantation that can overcome the many practical and ethical issues surrounding foetal \ntissue. \nIn the first part of the thesis, the investigations on finding neuroprotective agents to support \ngraft survival and efficacy was achieved in the unilateral 6-OHDA lesioned rat model, treated \nwith chronic L-dopa, (the gold standard anti- Parkinson medication), prior to, and following, \ncell transplantation. The results revealed for the first time that Glucagon Like Peptide-1 (GLP- \n1) receptor agonists (exendin-4 and liraglutide) were capable of improving graft size and the \nmotor and behaviour recovery results from peripheral administration. Importantly, this \nprotection was affected by the presence or absence of L-dopa treatment, as exendin-4 \nsupported the graft only in absence of L-dopa while liraglutide supported the graft only in the \npresence of L-dopa. While other neuroprotective agents (ghrelin and ghrelin receptor agonist) \nfailed to support graft survival or efficacy in the same animal model. In the second part of the \nthesis, the characterisation of different source of stem cells derived dopaminergic neurons \nrevealed for the first time that these cells can survive and function in the striatum of 6-OHDA \nrat model primed with chronic L-dopa treatment and exposed to L-dopa treatment for 16 \nweeks after transplantation. I show, for the first time, that these cells are capable of \nameliorating L-dopa induced dyskinesia.
Institution: Cardiff University
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2746967391
Cites: 347
Cited by:
Related to: 8